Absci Shares Fall on Wider 4Q Loss, Lower Revenue

Dow Jones03-25 18:36

By Connor Hart

Shares of Absci fell after the company widened its loss and logged lower revenue in the fourth quarter.

The stock declined 12%, to $2.64, in premarket trading Wednesday. Through Tuesday's close, shares are up 3.8% over the past year.

The biopharmaceutical company late Tuesday posted a widened loss of $29.6 million for its three months ended Dec. 31, compared with a loss of $29 million a year earlier. The quarterly loss came in at 20 cents a share, compared with analyst expectations for a loss of 18 cents a share, according to FactSet.

Revenue slipped 2.3% to $650,000, missing the $1.4 million that Wall Street modeled.

Founder and CEO Sean McClain said Absci made progress advancing its in-development therapies over the past year, noting that the company is implementing artificial intelligence to design therapeutics faster and cheaper than the broader industry.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

March 25, 2026 06:36 ET (10:36 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622242022?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-25 18:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622242022","market":"us","top_or_hot":-1,"title":"Absci Shares Fall on Wider 4Q Loss, Lower Revenue","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Absci fell after the company widened its loss and logged lower revenue in the fourth quarter. \n</p>\n<p>\n  The stock declined 12%, to $2.64, in premarket trading Wednesday. Through Tuesday's close, shares are up 3.8% over the past year. \n</p>\n<p>\n  The biopharmaceutical company late Tuesday posted a widened loss of $29.6 million for its three months ended Dec. 31, compared with a loss of $29 million a year earlier. The quarterly loss came in at 20 cents a share, compared with analyst expectations for a loss of 18 cents a share, according to FactSet. \n</p>\n<p>\n  Revenue slipped 2.3% to $650,000, missing the $1.4 million that Wall Street modeled. \n</p>\n<p>\n  Founder and CEO Sean McClain said Absci made progress advancing its in-development therapies over the past year, noting that the company is implementing artificial intelligence to design therapeutics faster and cheaper than the broader industry. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 25, 2026 06:36 ET (10:36 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Absci Shares Fall on Wider 4Q Loss, Lower Revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbsci Shares Fall on Wider 4Q Loss, Lower Revenue\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-25 18:36</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Absci fell after the company widened its loss and logged lower revenue in the fourth quarter. \n</p>\n<p>\n  The stock declined 12%, to $2.64, in premarket trading Wednesday. Through Tuesday's close, shares are up 3.8% over the past year. \n</p>\n<p>\n  The biopharmaceutical company late Tuesday posted a widened loss of $29.6 million for its three months ended Dec. 31, compared with a loss of $29 million a year earlier. The quarterly loss came in at 20 cents a share, compared with analyst expectations for a loss of 18 cents a share, according to FactSet. \n</p>\n<p>\n  Revenue slipped 2.3% to $650,000, missing the $1.4 million that Wall Street modeled. \n</p>\n<p>\n  Founder and CEO Sean McClain said Absci made progress advancing its in-development therapies over the past year, noting that the company is implementing artificial intelligence to design therapeutics faster and cheaper than the broader industry. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 25, 2026 06:36 ET (10:36 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2622242022","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622242022","pubTimestamp":1774434960,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Absci fell after the company widened its loss and logged lower revenue in the fourth quarter.The stock declined 12%, to $2.64, in premarket trading Wednesday. Through Tuesday's close, shares are up 3.8% over the past year.The biopharmaceutical company late Tuesday posted a widened loss of $29.6 million for its three months ended Dec. 31, compared with a loss of $29 million a year earlier. The quarterly loss came in at 20 cents a share, compared with analyst expectations for a loss of 18 cents a share, according to FactSet.Revenue slipped 2.3% to $650,000, missing the $1.4 million that Wall Street modeled.Founder and CEO Sean McClain said Absci made progress advancing its in-development therapies over the past year, noting that the company is implementing artificial intelligence to design therapeutics faster and cheaper than the broader industry.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4121":"生命科学工具和服务","BK4139":"生物科技","ABSI":"Absci Corporation."},"translate_title":"Absci股价因第四季度亏损扩大、收入下降而下跌","themeId":"8603dabb40994e59ac78c04c930c0d49","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABSI":0.9},"content_text":"By Connor Hart \n\n\n \n\n\n  Shares of Absci fell after the company widened its loss and logged lower revenue in the fourth quarter. \n\n\n  The stock declined 12%, to $2.64, in premarket trading Wednesday. Through Tuesday's close, shares are up 3.8% over the past year. \n\n\n  The biopharmaceutical company late Tuesday posted a widened loss of $29.6 million for its three months ended Dec. 31, compared with a loss of $29 million a year earlier. The quarterly loss came in at 20 cents a share, compared with analyst expectations for a loss of 18 cents a share, according to FactSet. \n\n\n  Revenue slipped 2.3% to $650,000, missing the $1.4 million that Wall Street modeled. \n\n\n  Founder and CEO Sean McClain said Absci made progress advancing its in-development therapies over the past year, noting that the company is implementing artificial intelligence to design therapeutics faster and cheaper than the broader industry. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 25, 2026 06:36 ET (10:36 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622242022","isCrawlerRequest":true}